Melphalan, Dexametasone and Thalidomide, Autoloogous Stem Cell and Maintenance with Low Doses of Thalidomide

1. Abstract
1.1. Background: Treatment of patients with multiple myeloma (MM) have a great advances, however, it is appear that relapse and refractory stage continued to be the rule in this setting of patients, thus recently MM will be considered as an chronic disease, and
the strategies will be adequate, employ regimens with minor and toxicities.